Black, compared to white women treated with neoadjuvant chemotherapy for ER+/HER2- breast cancer also have a higher TMEM doorway score and macrophage density in the residual tumor tissue, which may contribute to poorer outcomes (223). The gene discussed is ERBB2; the disease is breast cancer.